Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2026 12:14 ET | Source: PridCor Therapeutics, LLC

PridCor Therapeutics Secures Global Antiviral Portfolio, Establishing Leadership in Treatment of Long COVID and Infection-Associated Chronic Illnesses

PridCor secures global antiviral portfolio with Phase 2b and Phase 3 assets to advance treatments for Long COVID and chronic illness.
April 16, 2026 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Publication of Positive Data Demonstrating Intranasal Anti-CD3 Antibody Attenuates Long COVID Neuroinflammation and Improves Cognitive Function

BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human,...
March 31, 2026 17:12 ET | Source: GJLaw

$20 Million COVID-19 Testing Fraud: Lawsuit Alleges Sterling Pathology in Seal Beach Engaged in Widespread Billing Fraud - GJLaw

A Los Angeles Superior Court judge rejected secrecy attempts by Sterling Pathology and its owner Dr. Chang Yang to shield alleged COVID-19 phantom tests
January 06, 2026 10:07 ET | Source: PridCor Therapeutics, LLC

PridCor Therapeutics Advances SHIELD Study Through Dual Regulatory and Scientific Milestones With Peer-Reviewed Publication and FDA IND Exemption for Long COVID Program

PridCor Therapeutics advances its SHIELD Long COVID study with a peer-reviewed publication and FDA confirmation of IND exemption.
November 06, 2025 20:12 ET | Source: React19

React19 Launches “This Is Our Shot” Campaign as U.S. Vaccine Injury Victims Continue to Go Unheard and Uncompensated

React19 launches “This Is Our Shot” to raise $1M for vaccine-injured Americans, after giving $1.4 Million in aid.
October 30, 2025 08:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules

Investment by Directors and Management demonstrates confidence in the Company Potential for an additional $1.8 million upon the exercise in full of warrants BOTHELL, Wash., Oct. 30, 2025 (GLOBE...
September 23, 2025 08:43 ET | Source: PridCor Therapeutics, LLC

PridCor Therapeutics Principal Investigator Dr. David Putrino Participates in National Long COVID Roundtable Convened by Secretary Robert F. Kennedy Jr.

TUSCALOOSA, Ala., Sept. 23, 2025 (GLOBE NEWSWIRE) -- PridCor Therapeutics today announced that Dr. David Putrino, principal investigator of the company’s SHIELD Study, participated in a national...
September 07, 2025 17:19 ET | Source: ThinkCareBelieve

ThinkCareBelieve: How Operation Warp Speed Saved The World

Washington, DC, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Link to ThinkCareBelieve's Operation Warp Speed Article: https://thinkcarebelieve.blog/2025/09/07/how-operation-warp-speed-saved/ Link to...
September 04, 2025 10:32 ET | Source: PridCor Therapeutics, LLC

PridCor Therapeutics Reports Positive Long COVID Case Series with Combination Antiviral Regimen

PridCor reports Long COVID case series: combo of valacyclovir, celecoxib & Paxlovid® shows significant, lasting symptom improvement.
September 04, 2025 08:00 ET | Source: Daxor Corporation

Daxor's Blood Volume Analysis Validated for COVID and Sepsis Patients in New Peer-Reviewed Pilot Study Published in the Journal of Critical Care

Study Demonstrates That Clinical Assessments of Fluid Status Are Often Inaccurate, Highlighting the Urgent Need for BVA and Other More Reliable Tools in Landmark Pilot Study Oak Ridge, TN, Sept. 04,...